AR068442A1 - Inhibidores de la epoxido hidrolasa soluble - Google Patents
Inhibidores de la epoxido hidrolasa solubleInfo
- Publication number
- AR068442A1 AR068442A1 ARP080103987A ARP080103987A AR068442A1 AR 068442 A1 AR068442 A1 AR 068442A1 AR P080103987 A ARP080103987 A AR P080103987A AR P080103987 A ARP080103987 A AR P080103987A AR 068442 A1 AR068442 A1 AR 068442A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- cycloalkyl
- compositions
- alkyl
- group
- Prior art date
Links
- 150000002118 epoxides Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 108020002908 Epoxide hydrolase Proteins 0.000 abstract 3
- 102100025357 Lipid-phosphate phosphatase Human genes 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 2
- -1 aminocarbonylamino, aminocarbonyloxy, aminosulfonylamino Chemical group 0.000 abstract 2
- 150000001733 carboxylic acid esters Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000004995 haloalkylthio group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 230000001631 hypertensive effect Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 150000003585 thioureas Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos amida, tioamida, urea y tiourea y composiciones que inhiben la epoxido hidrolasa soluble (sEH), métodos de preparacion de dichos compuestos y composiciones y métodos para el tratamiento de pacientes con dichos compuestos y composiciones. Los compuestos, composiciones y métodos son de utilidad en el tratamiento de una variedad de enfermedades mediadas por sEH, incluyendo enfermedades hipertensivas, cardiovasculares, inflamatorias y aquellas relacionadas con la diabetes. Reivindicacion 1: Un compuesto caracterizado porque es de formula (1) o una: sal farmacéuticamente aceptable del mismo, en donde: L1 es un enlace covalente, -NH-, o -CR'Rö- donde R' y Rö son en forma independiente H o alquilo o R' y Rö juntos forman un anillo cicloalquilo C3-6; L2 es un enlace covalente o -CH2-; A es cicloalquilo sustituido o heterocíclico opcionalmente sustituido; X se selecciona entre el grupo que consiste en -O-, -C(=O)-, -S-, -SO-, -SO2-; y X no se conecta a L2; cada R1se selecciona en forma independiente entre el grupo que consiste en alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, heterocicloalquilo, heterocicloalquilo sustituido, arilo, arilo sustituido, heteroarilo y heteroarilo sustituido, con la salvedad de que R1 no es piperidinilo sustituido; n es 0, 1, 2, 3 o 4; p es 0, 1, 2 o 3; Q es O o S; R se selecciona entre el grupo que consiste en: cicloalquilo C6-10, cicloalquilo C6-10 sustituido, y formula (2) en donde R4 y R8 son en forma independiente hidrogeno o fluor; R5, R6, y R7se seleccionan en forma independiente entre el grupo que consiste en hidrogeno, halo, alquilo, acilo, aciloxi, éster carboxílico, acilamino, aminocarbonilo, aminocarbonilamino, aminocarboniIoxi, aminosulfonilamino, (éster carboxílico)amino, aminosulfonilo, (sulfonilo sustituido)amino, haloalquilo, haloalcoxi, haloalquiltio, ciano; y alquilsulfonilo; con la salvedad de que cuando R es adamantilo, n es 0, y p es 2, X no es -C(=O)-.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97215607P | 2007-09-13 | 2007-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068442A1 true AR068442A1 (es) | 2009-11-18 |
Family
ID=40220787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103987A AR068442A1 (es) | 2007-09-13 | 2008-09-12 | Inhibidores de la epoxido hidrolasa soluble |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20090082423A1 (es) |
| AR (1) | AR068442A1 (es) |
| TW (1) | TW200930359A (es) |
| WO (1) | WO2009035927A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200317813A1 (en) | 2016-05-25 | 2020-10-08 | Johann Wolfgang Goethe-Universitat Frankfurt Am Main | Treatment and diagnosis of non-proliferative diabetic retinopathy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0655730B2 (ja) * | 1987-07-17 | 1994-07-27 | ザ ヌトラスウィート カンパニー | 強力甘味剤 |
| GB9504361D0 (en) * | 1995-03-04 | 1995-04-26 | Glaxo Spa | Heterocyclic compounds |
| CA2584342C (en) * | 2004-10-20 | 2013-04-30 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| TW200833663A (en) * | 2006-12-21 | 2008-08-16 | Astrazeneca Ab | Therapeutic agents |
-
2008
- 2008-09-05 WO PCT/US2008/075494 patent/WO2009035927A2/en not_active Ceased
- 2008-09-10 US US12/207,668 patent/US20090082423A1/en not_active Abandoned
- 2008-09-10 TW TW097134760A patent/TW200930359A/zh unknown
- 2008-09-12 AR ARP080103987A patent/AR068442A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009035927A2 (en) | 2009-03-19 |
| WO2009035927A8 (en) | 2010-05-27 |
| TW200930359A (en) | 2009-07-16 |
| WO2009035927A3 (en) | 2009-06-04 |
| US20090082423A1 (en) | 2009-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016522172A5 (es) | ||
| AR109958A1 (es) | Lactamas bicíclicas de piridona y sus métodos de uso | |
| AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| AR064389A1 (es) | Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen. | |
| PE20110835A1 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| PE20191532A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| PE20210414A1 (es) | Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| AR063458A1 (es) | Derivados de piridina inhibidores de 11beta hsd1 | |
| AR059338A1 (es) | N-fenilbenzotriazolilo como inhibidores de c-kit | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR080865A1 (es) | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| ES2381683T3 (es) | Compuestos de espiro-oxindol y sus usos como agentes terapéuticos | |
| AR047098A1 (es) | Derivados de arilanilina como agonistas del receptor adrenergico beta2 | |
| AR045389A1 (es) | Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido | |
| AR074862A1 (es) | Derivados de heterociclo biciclicos y sus metodos de uso | |
| DOP2011000083A (es) | Compuestos de amida utiles en terapia | |
| RU2018114077A (ru) | Биарильное производное и содержащее его лекарственное средство | |
| RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
| AR109650A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |